$1,199.00
In Stock
Indications for the drug Bavencio
– monotherapy in previously treated adult patients with metastatic Merkel cell carcinoma (MCM);
– first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed on first-line platinum-based induction chemotherapy (as monotherapy);
– advanced renal cell carcinoma in adults (in combination with axitinib as first-line therapy).
Active ingredient: avelumab
Prescription medicine
The drug is delivered from Germany
